News | April 28, 2025
Dr. Lal Path Labs posts Q4 FY25 consolidated PAT at Rs. 154.8 Cr
The company has reported total income of Rs. 628.4 crores during the period ended March 31, 2025
The company has reported total income of Rs. 628.4 crores during the period ended March 31, 2025
The positive opinions are based on applications submitted by Biosimilar Collaborations Ireland Limited
Syngene reported revenue growth of 11% year-on-year, and 8% sequentially crossing the Rs. 1,000 Cr in a quarter threshold for the first time
For the financial year ended March 31, 2025, Thyrocare has reported total income of Rs.702.18 crores
The 27 greenfield labs across the country ensure timely and accurate reporting
The newly inaugurated facility bridges this gap by offering metro-grade treatment closer to home
The EIR was issued following an inspection of the facility conducted from June 10 to June 13, 2024
Genomics is transforming the future of modern medicine and treatment modalities across specialties
Before joining Sun Pharma, Tulla served as Senior Vice President and Chief Commercial Head – Acute Cluster at Cipla
David joins HCTI with a distinguished career of over 22 years of corporate finance experience
Subscribe To Our Newsletter & Stay Updated
